Development and validation of a prediction model for VTE risk in gastric and esophageal cancer patients.

Front Pharmacol

Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Published: February 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: This study focuses on the risk of venous thromboembolism (VTE) in patients with gastric or esophageal cancer (GC/EC), investigating the risk factors for VTE in this population. Utilizing machine learning techniques, the research aims to develop an interpretable VTE risk prediction model. The goal is to identify patients with gastric or esophageal cancer who are at high risk of VTE at an early stage in clinical practice, thereby enabling precise anticoagulant prophylaxis and thrombus management.

Methods: This study is a real-world investigation aimed at predicting VTE in patients with GC/EC. Data were collected from inpatients diagnosed with GC/EC at Sichuan Provincial People's Hospital between 1 January 2018, and 31 June 2023. Using nine supervised learning algorithms, 576 prediction models were developed based on 56 available variables. Subsequently, a simplified modeling approach was employed using the top 12 feature variables from the best-performing model. The primary metric for assessing the predictive performance of the models was the area under the ROC curve (AUC). Additionally, the training data used to construct the best model in this study were employed to externally validate several existing assessment models, including the Padua, Caprini, Khorana, and COMPASS-CAT scores.

Results: A total of 3,742 cases of GC/EC patients were collected after excluding duplicate visit information. The study included 861 (23.0%) patients, of which 124 (14.4%) developed VTE. The top five models based on AUC for full-variable modeling are as follows: GBoost (0.9646), Logic Regression (0.9443), AdaBoost (0.9382), CatBoost (0.9354), XGBoost (0.8097). For simplified modeling, the models are: Simp-CatBoost (0.8811), Simp-GBoost (0.8771), Simp-Random Forest (0.8736), Simp-AdaBoost (0.8263), Simp-Logistic Regression (0.8090). After evaluating predictive performance and practicality, the Simp-GBoost model was determined as the best model for this study. External validation of the Padua score, Caprini score, Khorana score, and COMPASS-CAT score based on the training set of the Simp-GBoost model yielded AUCs of 0.4367, 0.2900, 0.5000, and 0.3633, respectively.

Conclusion: In this study, we analyzed the risk factors of VTE in GC/EC patients, and constructed a well-performing VTE risk prediction model capable of accurately identifying the extent of VTE risk in patients. Four VTE prediction scoring systems were introduced to externally validate the dataset of this study. The results demonstrated that the VTE risk prediction model established in this study held greater clinical utility for patients with GC/EC. The Simp-GB model can provide intelligent assistance in the early clinical assessment of VTE risk in these patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906997PMC
http://dx.doi.org/10.3389/fphar.2025.1448879DOI Listing

Publication Analysis

Top Keywords

vte risk
24
prediction model
16
vte
13
gastric esophageal
12
esophageal cancer
12
risk prediction
12
model
10
risk
10
patients
10
study
8

Similar Publications

This study aims to optimize the dynamic administration regimen of prophylactic enoxaparin in critically ill patients to reduce the risk of VTE, major bleeding, and 30-day all-cause mortality. We developed and internally and externally validated an artificial intelligence (AI) policy utilizing Double dueling deep Q network, using data from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database (training and internal test set) and the eICU Collaborative Research Database (eICU-CRD, external test set). We compared the performance among the AI policy, the clinician's policy, the weight-tiered policy, and the fixed 40- mg-once-daily (QD) policy.

View Article and Find Full Text PDF

Importance: Janus kinase (JAK) inhibitors are highly effective medications for several immune-mediated inflammatory diseases (IMIDs). However, safety concerns have led to regulatory restrictions.

Objective: To compare the risk of adverse events with JAK inhibitors vs tumor necrosis factor (TNF) antagonists in patients with IMIDs in head-to-head comparative effectiveness studies.

View Article and Find Full Text PDF

Objectives: The risk of major venous thromboembolism (VTE) among patients with COVID-19 is high but varies with disease severity. Estimate the incidence of lower extremity deep venous thrombosis (DVT) in critically ill hospitalized patients with COVID-19, validate the Wells score for DVT diagnosis, and determine patients' prognosis.

Methods: This was an observational follow-up study in the context of the diagnosis and prognosis of DVT.

View Article and Find Full Text PDF

Introduction: The management of bleeding and coagulation after total knee arthroplasty (TKA) has long been recognised as a significant challenge for orthopaedic surgeons. Despite the notable success of empirical anticoagulation in preventing venous thromboembolism (VTE) following TKA, the increased risk of postoperative bleeding has also raised extensive concern. Ecchymosis, as one of the most common manifestations indicating postoperative bleeding, holds the potential to indicate the balance of bleeding and hypercoagulation.

View Article and Find Full Text PDF

Introduction: Venous thromboembolism (VTE) is a leading cause of mortality in cancer patients, and a substantial number of patients are being treated with oral anticoagulants. We aim to assess the comparative effectiveness of direct oral anticoagulants (DOACs) compared to warfarin for VTE treatment in cancer patients.

Methods: In this retrospective cohort study, we included 2,367 cancer patients who are new users of oral anticoagulants (OACs) for VTE treatment from 2009 to 2021 in NHS Scotland.

View Article and Find Full Text PDF